Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Management of Drug and Alcohol Withdrawal
NEJM 348:1786-1795, Kosten,T.R. &O'Connor,P.G., 2003
Use of Benzodiazepines in Anxiety Disorders
NEJM 328:1398-1405, Shader,R.I.&Greenblatt,D.J., 1993
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Clinicopathologic Conference, Psychotic Disorder Due to a General Medical Condition (postictal psychosis)
NEJM 391:2036-2046, Case 37-2024, 2024
Prevalence of Cannabis Withdrawal Symptoms Among People with Regular or Dependent Use of Cannabinoids
JAMA doi:10.1001/JAMANETWORKOPEN.2020.2370, Bahji, A.,et al, 2020
The Acquired Metabolic Disorders of the Nervous System, Hypoglycemic Encephalopathy
Adams & Victors Principles of Neurology Chp 40, pg 1139, Ropper, A.H.,et al, 2014
Psychiatric Side Effects During Methysergide Treatment
JNNP 76:1037-1038, Cittadini,E. &Goadsby,P.J., 2005
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Generalized Anxiety Disorder in Stroke Patients
Stroke 27:270-275, Astrom,M., 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Seizure Disorder
Ciba Clin Symposia 46:4-34, Devinsky,O., 1994
Intranasal Midazolam for Claustrophobia in MRI
J Comput Assist Tomogr 17:991-992, Moss,M.L.,et al, 1993
Withdrawal Syndrome after the Double-Blind Cessation of Caffeine Cunsumption
NEJM 327:1109-1114, 11601992., Silverman,R.,et al, 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Wilson Disease:Clinical Presentation, Treatment, and Survival
Ann Int Med 115:720-726, Stremmel,W.,et al, 1991
"Doom Anxiety"and Delirium in Lidocaine Toxicity
Am J Psychiatry 144:159-163, Saravay,S.M.,et al, 1987
Benzodiazepines
NEJM 309:354-358, 410-4161983., Greenblatt,D.J.,et al, 1983
Benzodiazepines
NEJM 29l:l0ll, Nov 1974:29l:l239., Greenblatt,D.J.,et al, 1974